{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:09:04Z","timestamp":1793311744913,"version":"4.5.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04811-7","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T07:51:45Z","timestamp":1757749905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anlotinib in cancer therapy: mechanisms of action, clinical applications, and future perspectives"],"prefix":"10.1007","volume":"95","author":[{"given":"Jianhua","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chai Hong","family":"Yeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"4811_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04930-w","author":"R Yakubov","year":"2025","unstructured":"Yakubov R, Kaloti R, Persaud P, McCracken A, Zadeh G, Bunda S (2025) It\u2019s all downstream from here: RTK\/RAF\/MEK\/ERK pathway resistance mechanisms in glioblastoma. J Neurooncol. https:\/\/doi.org\/10.1007\/s11060-024-04930-w","journal-title":"J Neurooncol"},{"key":"4811_CR2","doi-asserted-by":"crossref","unstructured":"Roda D, Veiga P, Melo JB, Carreira IM, Ribeiro (2024) IP: principles in the management of glioblastoma. Genes (Basel) 15(4):501","DOI":"10.3390\/genes15040501"},{"key":"4811_CR3","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WTA van der Graaf","year":"2012","unstructured":"van der Graaf WTA, Blay J-Y, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London England) 379:1879\u20131886","journal-title":"Lancet (London England)"},{"issue":"6","key":"4811_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li J, Qin S, Xu R et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16(6):619\u2013629","journal-title":"Lancet Oncol"},{"key":"4811_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312","journal-title":"Lancet"},{"key":"4811_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd.2018.21","volume":"17","author":"FM Ferguson","year":"2018","unstructured":"Ferguson FM, Gray NS (2018) Kinase inhibitors: the road ahead. Nat Rev Drug Discov 17:353\u2013377","journal-title":"Nat Rev Drug Discov"},{"key":"4811_CR7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41419-021-03685-w","volume":"12","author":"Y Cao","year":"2021","unstructured":"Cao Y, Shan H, Liu M et al (2021) Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib. Cell Death Dis 12:396","journal-title":"Cell Death Dis"},{"key":"4811_CR8","first-page":"442","volume":"31","author":"Y Cao","year":"2023","unstructured":"Cao Y, Liu Y, Liu Y et al (2023) Effects of Decitabine Combined with Anlotinib on Proliferation and Apoptosis of Multiple Myeloma Cells. Zhongguo shi yan xue ye xue za zhi 31(2):442\u2013447","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"key":"4811_CR9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu Y-L, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947\u2013957","journal-title":"N Engl J Med"},{"key":"4811_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123\u2013132","journal-title":"N Engl J Med"},{"key":"4811_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113\u2013125","journal-title":"N Engl J Med"},{"key":"4811_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L (2018) Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 29:i10\u2013i19","journal-title":"Ann Oncol"},{"key":"4811_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01899-w","volume":"9","author":"C Tomuleasa","year":"2024","unstructured":"Tomuleasa C, Tigu A-B, Munteanu R et al (2024) Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct Target Ther 9:201","journal-title":"Signal Transduct Target Ther"},{"key":"4811_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117453","volume":"289","author":"X Pang","year":"2025","unstructured":"Pang X, Xu W, Liang J, Liu Y, Li H, Chen L (2025) Research progress and perspectives of dual-target inhibitors. Eur J Med Chem 289:117453","journal-title":"Eur J Med Chem"},{"key":"4811_CR15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3892\/ol.2020.11685","volume":"20","author":"Y Gao","year":"2020","unstructured":"Gao Y, Liu P, Shi R (2020) Anlotinib as a molecular targeted therapy for tumors. Oncol Lett 20:1001\u20131014","journal-title":"Oncol Lett"},{"key":"4811_CR16","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1097\/CM9.0000000000003231","volume":"137","author":"Z Guo","year":"2024","unstructured":"Guo Z, Jing X, Sun X, Sun S, Yang Y, Cao Y (2024) Tumor angiogenesis and anti-angiogenic therapy. Chin Med J (Engl) 137:2043\u20132051","journal-title":"Chin Med J (Engl)"},{"key":"4811_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","volume":"654","author":"B Lin","year":"2018","unstructured":"Lin B, Song X, Yang D, Bai D, Yao Y, Lu N (2018) Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1. Gene 654:77\u201386","journal-title":"Gene"},{"key":"4811_CR18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/ijc.32180","volume":"145","author":"G Wang","year":"2019","unstructured":"Wang G, Sun M, Jiang Y et al (2019) Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int J Cancer 145:979\u2013993","journal-title":"Int J Cancer"},{"key":"4811_CR19","first-page":"1","volume":"13","author":"J Xu","year":"2023","unstructured":"Xu J, Chen C, Sun K et al (2023) Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma. Front Oncol 13:1\u201312","journal-title":"Front Oncol"},{"key":"4811_CR20","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.2147\/CMAR.S252181","volume":"12","author":"Q Yang","year":"2020","unstructured":"Yang Q, Ni L, Imani S et al (2020) Anlotinib suppresses colorectal cancer proliferation and angiogenesis via Inhibition of AKT\/ERK signaling cascade. Cancer Manag Res 12:4937\u20134948","journal-title":"Cancer Manag Res"},{"key":"4811_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-024-01971-7","volume":"23","author":"H Li","year":"2024","unstructured":"Li H, Feng H, Zhang T et al (2024) CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib. Mol Cancer 23:1\u201319","journal-title":"Mol Cancer"},{"key":"4811_CR22","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"4811_CR23","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550","journal-title":"N Engl J Med"},{"key":"4811_CR24","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484\u20132496","journal-title":"N Engl J Med"},{"key":"4811_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-bli. Lancet Oncol 16:499\u2013508","journal-title":"Lancet Oncol"},{"key":"4811_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London England) 383:31\u201339","journal-title":"Lancet (London England)"},{"key":"4811_CR27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, Ciuleanu T-E, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665\u2013673","journal-title":"Lancet"},{"key":"4811_CR28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jare.2017.06.006","volume":"8","author":"AM Al-Abd","year":"2017","unstructured":"Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA, Ashour OM (2017) Anti-angiogenic agents for the treatment of solid tumors: potential pathways, therapy and current strategies - a review. J Adv Res 8:591\u2013605","journal-title":"J Adv Res"},{"key":"4811_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1634\/theoncologist.2014-0465","volume":"20","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Adjei AA (2015) Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist 20:660\u2013673","journal-title":"Oncologist"},{"key":"4811_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7555\/JBR.38.20240045","volume":"38","author":"L Liting","year":"2024","unstructured":"Liting L, Xin H, Jiaxin L et al (2024) Anlotinib reverses osimertinib resistance via inhibiting epithelial-to-mesenchymal transition and angiogenesis in non-small cell lung cancer. J Biomed Res 38:1\u201315","journal-title":"J Biomed Res"},{"key":"4811_CR31","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01562-2018","author":"J Lu","year":"2019","unstructured":"Lu J, Zhong H, Chu T et al (2019) Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01562-2018","journal-title":"Eur Respir J"},{"key":"4811_CR32","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41416-021-01340-x","volume":"125","author":"J Liang","year":"2021","unstructured":"Liang J, Jin Z, Kuang J et al (2021) The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis. Br J Cancer 125:390\u2013401","journal-title":"Br J Cancer"},{"key":"4811_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01857-6","volume":"9","author":"H Sha","year":"2024","unstructured":"Sha H, Tong F, Ni J et al (2024) First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel\/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial. Signal Transduct Target Ther 9:1\u201310","journal-title":"Signal Transduct Target Ther"},{"key":"4811_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1530\/ERC-17-0558","volume":"26","author":"X Ruan","year":"2019","unstructured":"Ruan X, Shi X, Dong Q et al (2019) Antitumor effects of anlotinib in thyroid cancer. Endocr Relat Cancer 26:153\u2013164","journal-title":"Endocr Relat Cancer"},{"key":"4811_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117126","volume":"177","author":"Z Song","year":"2024","unstructured":"Song Z, Gong B, Qu T, Chen Y, Zhao G, Jin Y, Zhao Q (2024) Anlotinib destabilizes PAX3-FOXO1 to induce rhabdomyosarcoma cell death via upregulating NEK2. Biomed Pharmacother 177:117126","journal-title":"Biomed Pharmacother"},{"key":"4811_CR36","first-page":"1624","volume":"21","author":"L Tang","year":"2019","unstructured":"Tang L, Yu W, Wang Y, Li H, Shen Z (2019) Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex 21:1624\u20131633","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"key":"4811_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-024-03020-1","volume":"316","author":"Q Yang","year":"2024","unstructured":"Yang Q, Li Q, Fan H (2024) Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry. Arch Dermatol Res 316:1\u201313","journal-title":"Arch Dermatol Res"},{"key":"4811_CR38","first-page":"5228713","volume":"2021","author":"Y Lu","year":"2021","unstructured":"Lu Y, Lin J, Duan M et al (2021) Anlotinib Suppresses Oral Squamous Cell Carcinoma Growth and Metastasis by Targeting the RAS Protein to Inhibit the PI3K\/Akt Signalling Pathway. Anal Cell Pathol (Amst) 2021:5228713","journal-title":"Anal Cell Pathol (Amst)"},{"key":"4811_CR39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2174\/1871520620666200718235748","volume":"21","author":"X Tang","year":"2021","unstructured":"Tang X, Zheng Y, Jiao D, Chen J, Liu X, Xiong S, Chen Q (2021) Anlotinib inhibits cell proliferation, migration and invasion via suppression of c-Met pathway and activation of ERK1\/2 pathway in H446 cells. Anticancer Agents Med Chem 21:747\u2013755","journal-title":"Anticancer Agents Med Chem"},{"key":"4811_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","volume":"11","author":"F Song","year":"2020","unstructured":"Song F, Hu B, Cheng J-W et al (2020) Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis 11:573","journal-title":"Cell Death Dis"},{"key":"4811_CR41","first-page":"1494","volume":"13","author":"J Chen","year":"2021","unstructured":"Chen J, Feng J, Fang Z et al (2021) Anlotinib suppresses MLL-rearranged acute myeloid leukemia cell growth by inhibiting SETD1A\/AKT-mediated DNA damage response. Am J Transl Res 13:1494\u20131504","journal-title":"Am J Transl Res"},{"key":"4811_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjorl.2024.101397","volume":"90","author":"H Song","year":"2024","unstructured":"Song H, Song Q, Zhao X, Yang Y, Mou Y, Li Y, Song X (2024) Anlotinib suppressed tumor cell proliferation and migration in hypopharyngeal carcinoma. Braz J Otorhinolaryngol 90:101397","journal-title":"Braz J Otorhinolaryngol"},{"key":"4811_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/1414-431x2023e13152","volume":"57","author":"B Zheng","year":"2024","unstructured":"Zheng B, Sun X, Zhang L et al (2024) Inhibition of anlotinib-induced autophagy attenuates invasion and migration by regulating epithelial-mesenchymal transition and cytoskeletal rearrangement through ATG5 in human osteosarcoma cells. Braz J Med Biol Res 57:1\u201312","journal-title":"Braz J Med Biol Res"},{"key":"4811_CR44","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-pathmechdis-051222-115023","volume":"20","author":"A Moyer","year":"2025","unstructured":"Moyer A, Tanaka K, Cheng EH (2025) Apoptosis in cancer biology and therapy. Annu Rev Pathol 20:303\u2013328","journal-title":"Annu Rev Pathol"},{"key":"4811_CR45","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1016\/j.bbrc.2018.08.098","volume":"503","author":"C He","year":"2018","unstructured":"He C, Wu T, Hao Y (2018) Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway. Biochem Biophys Res Commun 503:3093\u20133099","journal-title":"Biochem Biophys Res Commun"},{"key":"4811_CR46","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41419-020-02938-4","volume":"11","author":"L Yang","year":"2020","unstructured":"Yang L, Zhou X, Sun J et al (2020) Reactive oxygen species mediate anlotinib-induced apoptosis via activation of endoplasmic reticulum stress in pancreatic cancer. Cell Death Dis 11:766","journal-title":"Cell Death Dis"},{"key":"4811_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12935-020-01721-x","volume":"21","author":"Z Deng","year":"2021","unstructured":"Deng Z, Liao W, Wei W et al (2021) Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe. Cancer Cell Int 21:37","journal-title":"Cancer Cell Int"},{"key":"4811_CR48","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.2147\/CMAR.S243660","volume":"12","author":"H Hu","year":"2020","unstructured":"Hu H, Liu Y, Tan S, Xie XX, He J, Luo F, Wang L (2020) Anlotinib exerts anti-cancer effects on KRAS-mutated lung cancer cell through suppressing the MEK\/ERK pathway. Cancer Manag Res 12:3579\u20133587","journal-title":"Cancer Manag Res"},{"key":"4811_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107637","volume":"149","author":"R Zhao","year":"2025","unstructured":"Zhao R, Cui Y, Li D et al (2025) Anlotinib enhances the pro-apoptotic effect of APG-115 on acute myeloid leukemia cell lines by inhibiting the P13K\/AKT signaling pathway. Leuk Res 149:107637","journal-title":"Leuk Res"},{"key":"4811_CR50","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.7150\/jca.45618","volume":"12","author":"L-H Yan","year":"2021","unstructured":"Yan L-H, Zhang D, Mo S-S, Yuan H, Mo X-W, Zhao J-M (2021) Anlotinib suppresses metastasis and multidrug resistance via dual blockade of MET\/ABCB1 in colorectal carcinoma cells. J Cancer 12:2092\u20132104","journal-title":"J Cancer"},{"key":"4811_CR51","first-page":"219","volume":"16","author":"C Wang","year":"2023","unstructured":"Wang C, Cao Q, Zhang S et al (2023) Anlotinib enhances the therapeutic effect of bladder cancer with GSDMB expression: analyzed from TCGA bladder cancer database & mouse bladder cancer cell line. Pharmgenomics Pers Med 16:219\u2013228","journal-title":"Pharmgenomics Pers Med"},{"key":"4811_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2021.1610008","volume":"27","author":"F Hu","year":"2021","unstructured":"Hu F, Guo L, Yu J, Dai D, Xiong Y, He Y, Zhou W (2021) Using patient-derived xenografts to explore the efficacy of treating head-and-neck squamous cell carcinoma with anlotinib. Pathol Oncol Res 27:1610008","journal-title":"Pathol Oncol Res"},{"key":"4811_CR53","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1172\/JCI71603","volume":"124","author":"W Zheng","year":"2014","unstructured":"Zheng W, Aspelund A, Alitalo K (2014) Lymphangiogenic factors, mechanisms, and applications. J Clin Invest 124:878\u2013887","journal-title":"J Clin Invest"},{"key":"4811_CR54","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-017-0484-1","volume":"10","author":"M Garc\u00eda-Caballero","year":"2017","unstructured":"Garc\u00eda-Caballero M, Paupert J, Blacher S, Van de Velde M, Quesada AR, Medina MA, No\u00ebl A (2017) Targeting VEGFR-3\/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases. J Hematol Oncol 10:122","journal-title":"J Hematol Oncol"},{"key":"4811_CR55","doi-asserted-by":"publisher","first-page":"753","DOI":"10.20892\/j.issn.2095-3941.2020.0024","volume":"17","author":"T Qin","year":"2020","unstructured":"Qin T, Liu Z, Wang J et al (2020) Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling. Cancer Biol Med 17:753\u2013767","journal-title":"Cancer Biol Med"},{"key":"4811_CR56","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.2147\/DDDT.S426898","volume":"17","author":"S Li","year":"2023","unstructured":"Li S, Wang H (2023) Research progress on mechanism and management of adverse drug reactions of anlotinib. Drug Des Devel Ther 17:3429\u20133437","journal-title":"Drug Des Devel Ther"},{"key":"4811_CR57","doi-asserted-by":"crossref","unstructured":"Zhang X, Ma H, Gao Y, Liang Y, Du Y, Hao S, Ni T (2024) The tumor microenvironment: signal transduction. Biomolecules 14(4):438","DOI":"10.3390\/biom14040438"},{"key":"4811_CR58","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-21-2241","volume":"28","author":"Y Su","year":"2022","unstructured":"Su Y, Luo B, Lu Y et al (2022) Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma. Clin Cancer Res 28:793\u2013809","journal-title":"Clin Cancer Res"},{"key":"4811_CR59","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu S, Qin T, Liu Z et al (2020) Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis 11:309","journal-title":"Cell Death Dis"},{"key":"4811_CR60","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/jleuko\/qiae037","volume":"116","author":"Y Lv","year":"2024","unstructured":"Lv Y, Zhao H, Liu S et al (2024) Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials. J Leukoc Biol 116:544\u2013554","journal-title":"J Leukoc Biol"},{"key":"4811_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1738","author":"F Song","year":"2024","unstructured":"Song F, Hu B, Liang X et al (2024) Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor\u2010dependent CD8\u2009+\u2009T\u2010cell infiltration in hepatocellular carcinoma. Clin Transl Med. https:\/\/doi.org\/10.1002\/ctm2.1738","journal-title":"Clin Transl Med"},{"key":"4811_CR62","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12964-024-01857-7","volume":"22","author":"B Wilczy\u0144ski","year":"2024","unstructured":"Wilczy\u0144ski B, D\u0105browska A, Kulbacka J, Baczy\u0144ska D (2024) Chemoresistance and the tumor microenvironment: the critical role of cell-cell communication. Cell Commun Signal 22:486","journal-title":"Cell Commun Signal"},{"key":"4811_CR63","doi-asserted-by":"publisher","first-page":"109979","DOI":"10.1016\/j.isci.2024.109979","volume":"27","author":"M Tufail","year":"2024","unstructured":"Tufail M, Hu J-J, Liang J et al (2024) Hallmarks of cancer resistance. iScience 27:109979","journal-title":"iScience"},{"key":"4811_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104161","volume":"29","author":"Y Guo","year":"2024","unstructured":"Guo Y, Ashrafizadeh M, Tambuwala MM, Ren J, Orive G, Yu G (2024) P-glycoprotein (P-gp)-driven cancer drug resistance: biological profile, non-coding rnas, drugs and nanomodulators. Drug Discov Today 29:104161","journal-title":"Drug Discov Today"},{"key":"4811_CR65","doi-asserted-by":"publisher","first-page":"798837","DOI":"10.3389\/fphar.2021.798837","volume":"12","author":"G Wang","year":"2021","unstructured":"Wang G, Cao L, Jiang Y et al (2021) Anlotinib reverses multidrug resistance (MDR) in osteosarcoma by inhibiting P-Glycoprotein (PGP1) function in vitro and in vivo. Front Pharmacol 12:798837","journal-title":"Front Pharmacol"},{"key":"4811_CR66","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/2632014","author":"L Wang","year":"2024","unstructured":"Wang L, Xu L, Han S, Zhu X (2024) Anlotinib inhibits cisplatin resistance in non-small-cell lung cancer cells by inhibiting MCL-1 expression via MET\/STAT3\/Akt pathway. Can Respir J. https:\/\/doi.org\/10.1155\/2024\/2632014","journal-title":"Can Respir J"},{"key":"4811_CR67","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.21873\/anticanres.16936","volume":"44","author":"X Xu","year":"2024","unstructured":"Xu X, Wang Q, Shen L et al (2024) Anlotinib inhibits ovarian cancer and enhances cisplatinum sensitivity via suppressing NOTCH2 expression and stemness. Anticancer Res 44:1399\u20131407","journal-title":"Anticancer Res"},{"key":"4811_CR68","first-page":"2331","volume":"25","author":"Z-X Jia","year":"2021","unstructured":"Jia Z-X, Zhang Z, Li Z et al (2021) Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR\/JAK2\/STAT3 axis. Eur Rev Med Pharmacol Sci 25:2331\u20132343","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4811_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111493","volume":"138","author":"C Lu","year":"2021","unstructured":"Lu C, Zhang Q, Zhang H, Li X, Jiang Q, Yao J (2021) A small molecular multi-targeting tyrosine kinase inhibitor, anlotinib, inhibits pathological ocular neovascularization. Biomed Pharmacother 138:111493","journal-title":"Biomed Pharmacother"},{"key":"4811_CR70","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.21037\/tlcr-21-192","volume":"10","author":"T Li","year":"2021","unstructured":"Li T, Qian Y, Zhang C et al (2021) Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo. Transl Lung Cancer Res 10:1873\u20131888","journal-title":"Transl Lung Cancer Res"},{"key":"4811_CR71","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cas.13536","volume":"109","author":"C Xie","year":"2018","unstructured":"Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L (2018) Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci 109:1207\u20131219","journal-title":"Cancer Sci"},{"key":"4811_CR72","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0839","volume":"24","author":"A-P Zhou","year":"2019","unstructured":"Zhou A-P, Bai Y, Song Y et al (2019) Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase II clinical trial. Oncologist 24:e702\u2013e708","journal-title":"Oncologist"},{"key":"4811_CR73","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/igc.0000000000001129","volume":"28","author":"S Taurin","year":"2018","unstructured":"Taurin S, Yang C-H, Reyes M et al (2018) Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model. Int J Gynecol Cancer 28:152\u2013160","journal-title":"Int J Gynecol Cancer"},{"key":"4811_CR74","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/aps.2017.199","volume":"39","author":"C-C Zhong","year":"2018","unstructured":"Zhong C-C, Chen F, Yang J-L et al (2018) Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species. Acta Pharmacol Sin 39:1048\u20131063","journal-title":"Acta Pharmacol Sin"},{"key":"4811_CR75","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","volume":"9","author":"Y Sun","year":"2016","unstructured":"Sun Y, Niu W, Du F et al (2016) Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol 9:105","journal-title":"J Hematol Oncol"},{"key":"4811_CR76","doi-asserted-by":"publisher","first-page":"3619723","DOI":"10.1155\/2017\/3619723","volume":"2017","author":"W Sun","year":"2017","unstructured":"Sun W, Wang Z, Chen R et al (2017) Influences of Anlotinib on Cytochrome P450 Enzymes in Rats Using a Cocktail Method. Biomed Res Int 2017:3619723","journal-title":"Biomed Res Int"},{"key":"4811_CR77","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","volume":"35","author":"NP van Erp","year":"2009","unstructured":"van Erp NP, Gelderblom H, Guchelaar H-J (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692\u2013706","journal-title":"Cancer Treat Rev"},{"key":"4811_CR78","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1002\/cam4.2913","volume":"9","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Han B, Li K et al (2020) Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: subgroup analysis in the ALTER0303 trial. Cancer Med 9:2621\u20132630","journal-title":"Cancer Med"},{"key":"4811_CR79","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","volume":"24","author":"Y Chi","year":"2018","unstructured":"Chi Y, Fang Z, Hong X et al (2018) Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res 24:5233\u20135238","journal-title":"Clin Cancer Res"},{"key":"4811_CR80","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12072-021-10171-0","volume":"15","author":"Y Sun","year":"2021","unstructured":"Sun Y, Zhou A, Zhang W et al (2021) Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study). Hepatol Int 15:621\u2013629","journal-title":"Hepatol Int"},{"key":"4811_CR81","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1002\/cam4.5360","volume":"12","author":"L Yu","year":"2023","unstructured":"Yu L, Xu J, Qiao R, Han B, Zhong H, Zhong R (2023) Efficacy and safety of anlotinib combined with PD-1\/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer. Cancer Med 12:5372\u20135383","journal-title":"Cancer Med"},{"key":"4811_CR82","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.2147\/OTT.S205674","volume":"12","author":"L Shao","year":"2019","unstructured":"Shao L, Wang W, Song Z, Zhang Y (2019) The efficacy and safety of anlotinib treatment for advanced lung cancer. Onco Targets Ther 12:6549\u20136554","journal-title":"Onco Targets Ther"},{"key":"4811_CR83","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1093\/annonc\/mdq651","volume":"22","author":"J Beck","year":"2011","unstructured":"Beck J, Procopio G, Bajetta E et al (2011) Final results of the European advanced renal cell carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 22:1812\u20131823","journal-title":"Ann Oncol"},{"key":"4811_CR84","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","volume":"10","author":"ME Gore","year":"2009","unstructured":"Gore ME, Szczylik C, Porta C et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10:757\u2013763","journal-title":"Lancet Oncol"},{"key":"4811_CR85","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/cncr.24864","volume":"116","author":"WM Stadler","year":"2010","unstructured":"Stadler WM, Figlin RA, McDermott DF et al (2010) Safety and efficacy results of the advanced renal cell carcinoma Sorafenib expanded access program in North America. Cancer 116:1272\u20131280","journal-title":"Cancer"},{"key":"4811_CR86","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.critrevonc.2014.04.004","volume":"92","author":"W-X Qi","year":"2014","unstructured":"Qi W-X, Shen Z, Tang L-N, Yao Y (2014) Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. Crit Rev Oncol Hematol 92:71\u201382","journal-title":"Crit Rev Oncol Hematol"},{"key":"4811_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.628895","volume":"11","author":"Q Gao","year":"2021","unstructured":"Gao Q, Jiang Y, Li X et al (2021) Intratumoral injection of anlotinib hydrogel combined with radiotherapy reduces hypoxia in Lewis lung carcinoma xenografts: assessment by micro fluorine-18-fluoromisonidazole positron emission tomography\/computed tomography hypoxia imaging. Front Oncol 11:628895","journal-title":"Front Oncol"},{"key":"4811_CR88","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/1759-7714.13780","volume":"12","author":"L Guo","year":"2021","unstructured":"Guo L, Zhang L, Guan Y, Li Y, Zhang C, Guo Q (2021) In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy. Thorac Cancer 12:593\u2013602","journal-title":"Thorac Cancer"},{"key":"4811_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-023-04500-0","volume":"21","author":"L Yang","year":"2023","unstructured":"Yang L, Zhao Q, Yu J, Wang L (2023) The addition of anlotinib reduces the incidence of radiation and immunotherapy-induced pneumonia. J Transl Med 21:1\u20133","journal-title":"J Transl Med"},{"key":"4811_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00995","volume":"10","author":"J Shi","year":"2020","unstructured":"Shi J, Zhang Y, Wang J, Li J, Li Z (2020) Anlotinib combined with chemoradiotherapy exhibits significant therapeutic efficacy in esophageal squamous cell carcinoma. Front Oncol 10:995","journal-title":"Front Oncol"},{"key":"4811_CR91","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-00995-1","author":"Y Liu","year":"2024","unstructured":"Liu Y, Li F, Wang Q, Zhang Y, Tian S, Li B (2024) Anlotinib inhibits growth of human esophageal cancer TE-1 cells by negative regulating PI3K\/Akt signaling pathway. Discover Oncol. https:\/\/doi.org\/10.1007\/s12672-024-00995-1","journal-title":"Discover Oncol"},{"key":"4811_CR92","doi-asserted-by":"publisher","first-page":"370","DOI":"10.5306\/wjco.v11.i6.370","volume":"11","author":"D Zhao","year":"2020","unstructured":"Zhao D, Xie B, Yang Y, Yan P, Liang S-N, Lin Q (2020) Progress in immunotherapy for small cell lung cancer. World J Clin Oncol 11:370\u2013377","journal-title":"World J Clin Oncol"},{"key":"4811_CR93","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s00262-020-02641-5","volume":"69","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li L, Jiang Z, Wang B, Pan Z (2020) Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunol Immunother 69:2523\u20132532","journal-title":"Cancer Immunol Immunother"},{"key":"4811_CR94","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, Zheng F, Ren D et al (2018) Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 11:120","journal-title":"J Hematol Oncol"},{"key":"4811_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102289","volume":"53","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Sun X, Li Y, Wang J, Wang C, Pan Z, Yang Y (2025) Anlotinib induced ferroptosis through the p53\/xCT\/GPX4 pathway in non-small cell lung cancer. Transl Oncol 53:102289","journal-title":"Transl Oncol"},{"key":"4811_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-023-01907-y","volume":"22","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Xu S, Ren J, Jiang T, Zhang C, Yan Z (2023) Anlotinib affects systemic lipid metabolism and induces lipid accumulation in human lung cancer cells. Lipids Health Dis 22:1\u201313","journal-title":"Lipids Health Dis"},{"key":"4811_CR97","doi-asserted-by":"crossref","unstructured":"Lai S, Li P, Liu X et al (2024) Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial. Cancer Biol Med 21(5):433-444","DOI":"10.20892\/j.issn.2095-3941.2023.0373"},{"key":"4811_CR98","doi-asserted-by":"publisher","first-page":"e034685","DOI":"10.1136\/bmjopen-2019-034685","volume":"10","author":"J Wang","year":"2020","unstructured":"Wang J, Wu DX, Meng L, Ji G (2020) Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil Porassium capsules)\u2009+\u2009oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial. BMJ Open 10:e034685","journal-title":"BMJ Open"},{"key":"4811_CR99","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/bjc.2017.478","volume":"118","author":"B Han","year":"2018","unstructured":"Han B, Li K, Zhao Y et al (2018) Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer 118:654\u2013661","journal-title":"Br J Cancer"},{"key":"4811_CR100","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.21037\/apm-20-2096","volume":"9","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang Q, Miao L, Zhou Y (2020) Nivolumab in combination with anlotinib achieved remarkable efficacy in a patient with driver-negative lung squamous cell carcinoma and PS of 4. Ann Palliat Med 9:4384\u20134388","journal-title":"Ann Palliat Med"},{"key":"4811_CR101","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2174\/1389201021666200623132803","volume":"22","author":"Q Luo","year":"2021","unstructured":"Luo Q, Zhang S, Zhang D et al (2021) Effects and mechanisms of anlotinib and Dihydroartemisinin combination therapy in ameliorating malignant biological behavior of gastric cancer cells. Curr Pharm Biotechnol 22:523\u2013533","journal-title":"Curr Pharm Biotechnol"},{"key":"4811_CR102","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.21873\/invivo.12395","volume":"35","author":"S Peng","year":"2021","unstructured":"Peng S, Dong W, Chu Q et al (2021) Traditional Chinese medicine Brucea Javanica oil enhances the efficacy of anlotinib in a mouse model of liver-metastasis of small-cell lung cancer. In Vivo 35:1437\u20131441","journal-title":"In Vivo"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04811-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04811-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04811-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T16:03:13Z","timestamp":1757952193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04811-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4811"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04811-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,13]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applied.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applied.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}